NewsBenzingaStoke Therapeutics presenta datos de STK-002 que respaldan su potencial modificador de la enfermedad en la atrofia óptica autosómica dominante en la reunión anual AAO 2026 Stoke Therapeutics presenta datos de STK-002 que respaldan su potencial modificador de la enfermedad en la atrofia óptica autosómica dominante en la reunión anual AAO 2026 Benzinga 2026.10.12 12:07 (GMT+0) Open on Benzinga Other news Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion CoreWeave’s CEO Says the Market Doesn’t Understand His Company. Whether or Not It Does Isn’t What Matters Here. Chevron Stock Price Targets Are Up and Put Credit Spreads Are Attractive to Value Players Traders Give Google a 70% Chance of Having the Best AI Model. Most People Can’t Even Use It Yet. Apple updates guidelines to ban nudify apps masquerading as regular apps to pass review Ahead of General Motors Earnings, Here's What Barchart Data Says Comes Next for GM Stock
Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 6.04 Million Tokens, and Total Crypto and Total Cash & Marketable Securities Holdings of $15.1 Billion
CoreWeave’s CEO Says the Market Doesn’t Understand His Company. Whether or Not It Does Isn’t What Matters Here.
